Clinical characteristics of 57 patients who underwent allogeneic HSCT
| Characteristic . | Chronic GVHD . | |||
|---|---|---|---|---|
| Active . | Inactive . | No . | P . | |
| No. (%) | 22 (45) | 23 (36) | 12 (18) | |
| Median age, y (range) | 46 (24-64) | 47 (19-66) | 44 (25-58) | .65 |
| Female sex (%) | 10 (45) | 11 (48) | 4 (33) | .73 |
| Conditioning regimen (%) | ||||
| Myeloablative | 14 (64) | 17 (74) | 10 (83) | .52 |
| Nonmyeloablative | 8 (36) | 6 (26) | 2 (17) | |
| Cell source (%) | ||||
| Peripheral blood stem cells | 19 (86) | 15 (65) | 9 (75) | .26 |
| Bone marrow | 3 (14) | 8 (35) | 3 (25) | |
| HLA matching (%) | ||||
| Matched, unrelated | 10 (45) | 13 (57) | 2 (17) | .11 |
| Matched, related | 11 (50) | 9 (39) | 10 (83) | |
| Mismatched | 1 (5) | 1 (4) | 0 (0) | |
| Prednisone dose (%) | ||||
| 0 mg/day | 9 (30) | 10 (42) | 11 (92) | |
| 0-30 mg/day | 13 (59) | 13 (57) | 1 (8) | |
| Cellcept (%) | 7 (32) | 5 (21) | 0 (0) | |
| Tacrolimus (%) | 8 (36) | 3 (13) | 0 (0) | |
| Rapamycin (%) | 8 (36) | 3 (13) | 0 (0) | |
| Months after transplantation, median (range) | 20.9 (13.6-79.2) | 30.9 (16.7-134.6) | 26.6 (18.7-93.2) | .01* |
| BAFF level, ng/mL, median (range) | 7.0 (1.6-24.5) | 5.5 (1.5-24.3) | 3.0 (1.4-4.9) | .001 |
| Grades II-IV aGVHD (%) | 2 (9) | 5 (22) | 2 (17) | .52 |
| Disease (%) | ||||
| AML/AML from MDS | 8 (36) | 5 (22) | 2 (17) | |
| ALL | 2 (9) | 1 (4) | 3 (25) | |
| CML | 0 (0) | 9 (39) | 3 (25) | |
| CLL | 3 (14) | 0 (0) | 0 (0) | |
| MDS | 4 (18) | 4 (17) | 0 (0) | |
| NHL | 2 (9) | 1 (4) | 4 (33) | |
| HL | 1 (5) | 0 (0) | 0 (0) | |
| MM | 0 (0) | 1 (4) | 0 (0) | |
| Other | 2 (9) | 2 (9) | 0 (0) | |
| Characteristic . | Chronic GVHD . | |||
|---|---|---|---|---|
| Active . | Inactive . | No . | P . | |
| No. (%) | 22 (45) | 23 (36) | 12 (18) | |
| Median age, y (range) | 46 (24-64) | 47 (19-66) | 44 (25-58) | .65 |
| Female sex (%) | 10 (45) | 11 (48) | 4 (33) | .73 |
| Conditioning regimen (%) | ||||
| Myeloablative | 14 (64) | 17 (74) | 10 (83) | .52 |
| Nonmyeloablative | 8 (36) | 6 (26) | 2 (17) | |
| Cell source (%) | ||||
| Peripheral blood stem cells | 19 (86) | 15 (65) | 9 (75) | .26 |
| Bone marrow | 3 (14) | 8 (35) | 3 (25) | |
| HLA matching (%) | ||||
| Matched, unrelated | 10 (45) | 13 (57) | 2 (17) | .11 |
| Matched, related | 11 (50) | 9 (39) | 10 (83) | |
| Mismatched | 1 (5) | 1 (4) | 0 (0) | |
| Prednisone dose (%) | ||||
| 0 mg/day | 9 (30) | 10 (42) | 11 (92) | |
| 0-30 mg/day | 13 (59) | 13 (57) | 1 (8) | |
| Cellcept (%) | 7 (32) | 5 (21) | 0 (0) | |
| Tacrolimus (%) | 8 (36) | 3 (13) | 0 (0) | |
| Rapamycin (%) | 8 (36) | 3 (13) | 0 (0) | |
| Months after transplantation, median (range) | 20.9 (13.6-79.2) | 30.9 (16.7-134.6) | 26.6 (18.7-93.2) | .01* |
| BAFF level, ng/mL, median (range) | 7.0 (1.6-24.5) | 5.5 (1.5-24.3) | 3.0 (1.4-4.9) | .001 |
| Grades II-IV aGVHD (%) | 2 (9) | 5 (22) | 2 (17) | .52 |
| Disease (%) | ||||
| AML/AML from MDS | 8 (36) | 5 (22) | 2 (17) | |
| ALL | 2 (9) | 1 (4) | 3 (25) | |
| CML | 0 (0) | 9 (39) | 3 (25) | |
| CLL | 3 (14) | 0 (0) | 0 (0) | |
| MDS | 4 (18) | 4 (17) | 0 (0) | |
| NHL | 2 (9) | 1 (4) | 4 (33) | |
| HL | 1 (5) | 0 (0) | 0 (0) | |
| MM | 0 (0) | 1 (4) | 0 (0) | |
| Other | 2 (9) | 2 (9) | 0 (0) | |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphoblastic leukemia; NHL, non-Hodgkin leukemia; HL, Hodgkin lymphoma; and MM, multiple myeloma.
P = .101 for active group versus none; P = .007 for active versus inactive group.